Rasvumine kliinilised uuringud osariigis Idaho
21 uuringut haiguse Rasvumine jaoks otsivad osalejaid osariigis Idaho.
Linnad osariigis Idaho
Ametlik uuringutekst (inglise keeles)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Elite Clinical Trials - Blackfoot /ID# 282042, Blackfoot
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 2. okt 2026 · NCT07752979A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Solaris Clinical Research, Meridian
VärbamineFaas 3
Vanused 8–18 · Kõik sood · Uuendatud 30. sept 2026 · NCT07253285Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Grand Teton Research Group, Idaho Falls
VärbamineFaas 3
Vanused 18–70 · Kõik sood · Uuendatud 24. sept 2026 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Grand Teton Research Group, Idaho Falls
VärbamineFaas 3
Vanused 18–70 · Kõik sood · Uuendatud 24. sept 2026 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Family First Medical Center, Idaho Falls
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07392190Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Velocity Clinical Research - Boise, Meridian
VärbamineFaas 3
Vanused 45–99 · Kõik sood · Uuendatud 22. sept 2026 · NCT07037433Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Medical Research Partners, Ammon
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. sept 2026 · NCT07353931A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Medical Research Partners, Ammon
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 22. sept 2026 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Boise
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 16. sept 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Boise
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 16. sept 2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- High Desert Heart and Vascular, Meridian
VärbamineFaas 3
Vanused 18–99 · Kõik sood · Uuendatud 16. sept 2026 · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Elite Clinical Trials, Blackfoot
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 14. sept 2026 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Elite Clinical Trials, Rexburg
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 14. sept 2026 · NCT06897475A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Meridian
VärbamineFaas 3Terved vabatahtlikud oodatud
Vanused 18–79 · Kõik sood · Uuendatud 11. sept 2026 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Medical Research Partners, Ammon
VärbamineFaas 2
Vanused 18–75 · Kõik sood · Uuendatud 8. sept 2026 · NCT06143956Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Solaris Clinical Research, Meridian
VärbamineFaas 3
Vanused 18–99 · Kõik sood · Uuendatud 3. sept 2026 · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Solaris Clinical Research, Meridian
VärbamineFaas 3
Vanused 18–99 · Kõik sood · Uuendatud 27. aug 2026 · NCT07575399A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- High Desert Heart and Vascular PLLC, Meridian
- St. Luke's Idaho Cardiology Associates, Meridian
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 18. aug 2026 · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Meridian
- ACCOMPLISH-1 Research Site, Rexburg
VärbamineFaas 3
Vanused 18–79 · Kõik sood · Uuendatud 10. aug 2026 · NCT07654361Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention
- Boise VA Medical Center, Boise
Värbamine
Vanused 18 ja vanemad · Kõik sood · Uuendatud 22. juuli 2026 · NCT06390345A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Elite Clinical Trials, Blackfoot
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 9. juuli 2026 · NCT07481630Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.